Content area
Full Text
Biologic therapy is more costly than triple therapy for first-line treatment of active rheumatoid arthritis (RA) and unlikely to be cost effective, according to findings of an analysis of published in Annals of Internal Medicine.1
A decision analytic model based on data in 324 participants in the Rheumatoid Arthritis Comparison of Active Therapies (RACAT) trial was used to evaluate the cost effectiveness of etanercept + methotrexate as first-line treatment, compared with triple therapy with conventional disease-modifying antirheumatic drugs, in patients with active RA despite methotrexate treatment for 12 weeks or longer, from US Medicare and societal perspectives over...